Vaccine + Chemotherapy + Monoclonal Antibody Therapy for Breast Cancer

Overseen By Jennifer Childs

Age: 18+

Sex: Any

Trial Phase: Phase 2

Sponsor: University of Washington

Must be taking: Chemotherapy, HER2-targeted therapy

Must not be taking: Immunosuppressants, Corticosteroids

Disqualifiers: Cardiomyopathy, Autoimmune disease, HIV, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Prior Safety Data This treatment has passed at least one previous human trial

Compensation: Varies

Number of Visits: Unknown

Duration: 12 weeks

25 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial explores a new treatment combination for breast cancer using a vaccine called WOKVAC (pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine) alongside chemotherapy and HER2-targeted therapies. The goal is to assess how effectively this approach helps the immune system fight cancer and to understand its side effects. The treatment includes paclitaxel, trastuzumab, and pertuzumab, which aim to kill cancer cells and block growth signals in tumor cells. Individuals with HER2-positive breast cancer planning to undergo specific chemotherapy and antibody treatments might be suitable candidates for this trial. As a Phase 2 trial, the research focuses on measuring the treatment's effectiveness in an initial, smaller group of participants.

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications. However, if you are using immunosuppressive agents or systemic corticosteroids, you may need to stop, as these are not allowed in the trial.

Is there any evidence suggesting that this trial's treatments are likely to be safe?

Research shows that the treatments in this trial have been used before, providing some known safety information. Paclitaxel, a chemotherapy drug, works effectively at various doses, with lower doses typically causing fewer side effects. Patients treated with paclitaxel have shown good survival rates, and it is considered safe when combined with other treatments.

Trastuzumab and pertuzumab target HER2 receptors on breast cancer cells. They attach to these cells, blocking growth signals and aiding the immune system in destroying them. These drugs are well-known for their safety and are generally well-tolerated by patients.

The WOKVAC vaccine is newer, so less information is available about it. This trial is in an early stage, meaning its safety is still under close observation. If the vaccine is being tested in humans, earlier studies have shown it to be somewhat safe.

Overall, while paclitaxel, trastuzumab, and pertuzumab have established safety records, the safety of the WOKVAC vaccine is still under study. Participants should consult their healthcare provider to understand any potential risks. ^{1 2 3 4 5}

Why are researchers excited about this trial's treatments?

Researchers are excited about this breast cancer treatment because it combines a vaccine, chemotherapy, and monoclonal antibody therapy in a novel way. Unlike typical treatments that often focus on just chemotherapy or monoclonal antibodies like trastuzumab, this approach includes a new plasmid DNA vaccine called pUMVC3-IGFBP2-HER2-IGF1R. This vaccine aims to stimulate the immune system to specifically target cancer cells, potentially enhancing the effectiveness of traditional therapies. By attacking cancer from multiple angles, this treatment could offer a more comprehensive approach to stopping tumor growth and improving patient outcomes.

What evidence suggests that this trial's treatments could be effective for breast cancer?

In this trial, participants will receive a combination of treatments, including paclitaxel, trastuzumab, pertuzumab, and the WOKVAC vaccine. Research has shown that paclitaxel effectively treats breast cancer, with studies indicating that patients who received it responded better and experienced a longer period before their disease worsened. Trastuzumab and pertuzumab are targeted treatments that attach to specific parts of cancer cells called HER2 receptors. By doing this, they block signals that promote cancer growth and help the immune system destroy the tumor. Vaccines like WOKVAC are designed to boost the body's immune response to fight cancer cells. Although the vaccine is newer and less studied, using it alongside chemotherapy and targeted treatments like trastuzumab and pertuzumab may enhance overall effectiveness in treating breast cancer. ^{4 5 6 7 8}

Who Is on the Research Team?

William Gwin

Principal Investigator

Fred Hutch/University of Washington Cancer Consortium

Are You a Good Fit for This Trial?

This trial is for adults with HER2+ stage I-III breast cancer who plan to undergo neoadjuvant therapy. They must have adequate organ function, agree to use contraception if of child-bearing potential, and not be on immunosuppressants or other investigational drugs. Exclusions include HIV-positive individuals, uncontrolled autoimmune diseases, recent major surgery, certain heart conditions, and known allergies to vaccine components.

Inclusion Criteria

I have stage I-III HER2+ breast cancer and will start treatment soon.

Your platelet count is at least 75,000 per microliter within the past 4 weeks before starting the study treatment.

Your white blood cell count is at least 500 per cubic millimeter.

Exclusion Criteria

You are allergic to the GM-CSF adjuvant.

I have not had major surgery in the last 4 weeks.

I have had hepatitis B or C but it has been treated and cleared.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive WOKVAC vaccine, paclitaxel, trastuzumab, and pertuzumab. WOKVAC is administered intradermally on day 13, paclitaxel via infusion on days 1, 8, and 15, and trastuzumab and pertuzumab intravenously on day 1. Treatment repeats for up to 4 cycles.

12 weeks

Surgery

Surgical resection of the tumor is performed after completion of the treatment cycles.

1 week

Follow-up

Participants are monitored for safety and effectiveness after treatment, with annual follow-ups for up to 5 years.

5 years

What Are the Treatments Tested in This Trial?

Interventions

• Paclitaxel
• Pertuzumab
• pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine
• Trastuzumab

Trial Overview The study tests the WOKVAC vaccine combined with chemotherapy (paclitaxel) and HER2-targeted monoclonal antibody therapy (trastuzumab and pertuzumab) before surgery in patients with breast cancer. The goal is to see if this combination can better stimulate the immune system to attack tumor cells compared to standard treatments alone.

How Is the Trial Designed?

Group I: Treatment (WOKVAC, paclitaxel, trastuzumab, pertuzumab) Experimental Treatment 9 Interventions

Patients receive WOKVAC ID on day 13. Treatment repeats for up to 3 cycles in the absence of disease progression or unacceptable toxicity. Patients also receive paclitaxel via infusion on days 1, 8, and 15 or docetaxel IV and carboplatin IV on day 1, and trastuzumab IV and pertuzumab IV on day 1. The chemo and trastuzumab and pertuzumab will most likely be given by the patient's own oncologist per standard of care. Treatment repeats for up to 4 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo ultrasound imaging or magnetic resonance imaging and biopsy on study and blood sample collection throughout the study.

Paclitaxel is already approved in United States, European Union, Canada for the following indications:

Approved in United States as Taxol for:

• Ovarian cancer
• Breast cancer
• Non-small cell lung cancer
• Kaposi's sarcoma

Approved in European Union as Taxol for:

• Ovarian cancer
• Breast cancer
• Non-small cell lung cancer
• Kaposi's sarcoma

Approved in Canada as Paclitaxel for:

• Ovarian cancer
• Breast cancer
• Non-small cell lung cancer
• Kaposi's sarcoma

Who Is Running the Clinical Trial?

University of Washington

Lead Sponsor

Trials

1,858

Recruited

2,023,000+

United States Department of Defense

Collaborator

Trials

940

Recruited

339,000+

Published Research Related to This Trial

The TCHP regimen (docetaxel, carboplatin, trastuzumab, and pertuzumab) demonstrated an acceptable safety profile in older postmenopausal women with nonmetastatic HER2-positive breast cancer, with no severe cardiac dysfunction observed.

While both TCHP and TCP regimens had similar mild toxicities, the TCHP group experienced higher rates of febrile neutropenia and hospitalization due to treatment-related toxicities, suggesting careful monitoring is needed.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Safety Assessment of Neoadjuvant Pertuzumab Combined with Trastuzumab in Nonmetastatic HER2-Positive Breast Cancer in Postmenopausal Elderly Women of South Asia. Hussain, N., Said, ASA., Khan, Z.[2022]

In a case series of 19 patients with previously treated HER2-positive metastatic breast cancer, the combination of pertuzumab, trastuzumab, and taxane therapy resulted in a median progression-free survival of 4.1 months.

The treatment was associated with minimal adverse effects, showing only a slight decrease in left ventricular ejection fraction (-1%) and no occurrences of neutropenic fever, suggesting a favorable safety profile.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Combination pertuzumab, trastuzumab, and taxane for metastatic breast cancer after first progression: a single institution's experience. Dao, BD., Ho, H., Quintal, LN.[2016]

Pertuzumab, a monoclonal antibody targeting HER2, significantly improves progression-free survival in patients with HER2-positive metastatic breast cancer, with a median of 18.5 months compared to 12.4 months for the placebo group, based on a phase III trial with previously untreated patients.

While the overall safety profile of pertuzumab is similar to placebo, it is associated with a higher incidence of specific side effects such as diarrhea, rash, and neutropenia, indicating the need for monitoring during treatment.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

The European Medicines Agency Review of Pertuzumab for the treatment of adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer: summary of the scientific assessment of the committee for medicinal products for human use. Boix-Perales, H., Borregaard, J., Jensen, KB., et al.[2023]

In a study of 152 patients with HER2-positive metastatic breast cancer, the combination of taxanes with trastuzumab and pertuzumab showed a significant progression-free survival (PFS) advantage over vinorelbine in patients with newly diagnosed metastatic disease, indicating a potential benefit for this specific group.

Overall, there was no significant difference in overall survival (OS) between the two treatment groups, suggesting that both taxanes and vinorelbine are viable options when combined with trastuzumab and pertuzumab for first-line treatment.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Taxane versus vinorelbine in combination with trastuzumab and pertuzumab for first-line treatment of metastatic HER2-positive breast cancer: a retrospective two-center study. Reinhorn, D., Kuchuk, I., Shochat, T., et al.[2021]

In a mouse model of breast cancer, combining a modified HER2/neu DNA vaccine with the monoclonal antibody trastuzumab resulted in significant tumor regression, suggesting a promising new treatment strategy.

This combination therapy may enhance the efficacy of trastuzumab, which is often limited by resistance in breast cancer patients, indicating potential clinical benefits for those with HER2/neu-positive tumors.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Combination of epitope-optimized DNA vaccination and passive infusion of monoclonal antibody against HER2/neu leads to breast tumor regression in mice. Orlandi, F., Guevara-Patiño, JA., Merghoub, T., et al.[2017]

In a phase III trial involving patients with high-risk HER2-positive early breast cancer, the addition of atezolizumab to standard treatment (pertuzumab-trastuzumab and chemotherapy) did not significantly improve the rates of pathologic complete response (pCR) compared to placebo, with pCR rates being 62.7% for placebo and 62.4% for atezolizumab in the overall population.

While the safety profile of atezolizumab was consistent with previous studies, it was associated with a higher frequency of serious adverse events, including five grade 5 adverse events, indicating a need for careful consideration of its use in combination therapies.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Atezolizumab With Neoadjuvant Anti-Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial. Huober, J., Barrios, CH., Niikura, N., et al.[2022]

The AE37 vaccine, which targets the HER-2/neu protein in breast cancer, has been shown to be safe and effective in generating long-lasting immune responses in patients, regardless of their HER-2/neu expression levels.

Early clinical trials indicate that the AE37 vaccine may help prevent breast cancer recurrence, highlighting its potential as a promising immunotherapy option.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

AE37: a novel T-cell-eliciting vaccine for breast cancer. Sears, AK., Perez, SA., Clifton, GT., et al.[2014]

The Her2-plasmid DNA vaccine, administered alongside GM-CSF and IL-2, was found to be safe and well-tolerated in patients with metastatic Her2-expressing breast cancer, with no acute toxicity or autoimmune reactions observed.

The vaccine successfully induced long-lasting Her2-specific antibody production in some patients, demonstrating its potential to stimulate an immune response against breast cancer, even though immediate T-cell responses were not significantly observed.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial. Norell, H., Poschke, I., Charo, J., et al.[2023]

In a study of 57 patients with HER2-positive breast cancer receiving neoadjuvant treatment with doxorubicin and cyclophosphamide followed by trastuzumab and pertuzumab, only 3.5% developed severe heart failure, indicating a relatively low cardiac event rate.

The study found no increased risk of cardiotoxicity from the combination of trastuzumab and pertuzumab after doxorubicin-based chemotherapy, suggesting that this treatment regimen is cardiac safe for patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer. Yu, AF., Singh, JC., Wang, R., et al.[2018]

In the TRAIN-2 study involving 110 patients with HER2-positive breast cancer, the addition of pertuzumab to chemotherapy regimens resulted in neutropenia as the most common hematologic toxicity, affecting 53% of patients in the FEC-T arm and 51% in the PTC arm.

While both regimens showed manageable toxicity, the FEC-T arm had a higher incidence of asymptomatic ejection fraction decrease (24%) compared to the PTC arm (11%), and diarrhea was more common in the PTC arm (18% vs. 5%), indicating different toxicity profiles depending on the chemotherapy backbone used.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study. van Ramshorst, MS., van Werkhoven, E., Honkoop, AH., et al.[2022]

The development of a protein vaccine targeting HER-2/neu aims to induce a humoral anti-tumor response, potentially enhancing the effects of existing monoclonal antibody therapies like Trastuzumab.

The vaccine has undergone extensive testing in animal models and toxicology programs, leading to its evaluation in three clinical trials involving breast cancer patients, highlighting its potential as a complementary treatment strategy.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Perspectives on the development of a therapeutic HER-2 cancer vaccine. Renard, V., Leach, DR.[2014]

Citations

1. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC9016319/

A Real-World Efficacy of Nab-Paclitaxel Monotherapy in ... In conclusion, this real-world data shows that nab-paclitaxel is an effective treatment option in metastatic breast cancer. Nab-paclitaxel was well tolerated ...

2. ascopubs.org ascopubs.org/doi/10.1200/JCO.19.00877

Nab-Paclitaxel: A New Standard of Care in Neoadjuvant ... Outcome Data for Trials of Nab-Paclitaxel in Metastatic Breast Cancer. A subsequent phase II trial in 302 patients with metastatic disease ...

3. clinical-breast-cancer.com clinical-breast-cancer.com/article/S1526-8209(18)30064-8/fulltext

Final Effectiveness and Safety Results of NABUCCO A total of 697 patients had evaluable data with a median follow-up of 17.7 months. Median time to progression was 5.9 months (95% confidence ...

4. nature.com nature.com/articles/s41598-019-57380-0

Efficacy and safety of nanoparticle-albumin-bound ... Nab-paclitaxel is an effective anti-tumor drug in the first-line treatment of MBC. Using nab-paclitaxel instead of sb-taxanes could ...

5. bmccancer.biomedcentral.com bmccancer.biomedcentral.com/articles/10.1186/s12885-021-08441-z

A systematic review and meta-analysis of nab-paclitaxel ... Patients who received first-line nab-paclitaxel monotherapy showed a higher ORR (P = 0.006) and longer PFS (P = 0.045). Efficacy outcomes were ...

6. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC3143911/

Nab-paclitaxel for the treatment of breast cancer Weekly administration of 100 mg/m2 nab-paclitaxel showed the same antitumor activity as 125 mg/m2, with the benefit of a more favorable toxicity profile in ...

7. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC11672372/

Efficacy and Safety of Paclitaxel-Based PD-1/PD-L1 ... When combined with paclitaxel, PD-1/PD-L1 inhibitors exhibit a favorable survival benefit. The combination of Durvalumab and paclitaxel represents the optimal ...

8. cancertherapyadvisor.com cancertherapyadvisor.com/reports/paclitaxel-and-nab-paclitaxel-deemed-comparable-in-high-risk-early-breast-cancer/

Paclitaxel and Nab-Paclitaxel Deemed Comparable for ... The 5-year overall survival rate was 92.9% in the paclitaxel arm and 94.0% in the nab-paclitaxel arm (HR, 0.93; 95% CI, 0.66-1.31; Cox ...